Literature DB >> 19035779

Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007.

Carmen Ardanuy1, Fe Tubau, Román Pallares, Laura Calatayud, María Angeles Domínguez, Dora Rolo, Inmaculada Grau, Rogelio Martín, Josefina Liñares.   

Abstract

BACKGROUND: A dramatic decrease in the incidence of invasive pneumococcal disease (IPD) was observed among children and adults in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). Little is known about the incidence of IPD after PCV7 licensure in Europe. The objective of this study was to examine changes in the prevalence of IPD among adults in the PCV7 era.
METHODS: We undertook a prospective study involving adults with IPD who required hospital admission in the southern area of Barcelona, Spain. Three periods were studied: the pre-PCV7 period (1997-2001), the early PCV7 period (2002-2004), and the late PCV7 period (2005-2007).
RESULTS: A total of 1007 episodes of IPD were observed. Rates of IPD among adults increased from 13.9 to 14.6 episodes per 100,000 population between the pre-PCV7 period and the early PCV7 period (P = .6) and then to 19.55 episodes per 100,000 population in the late PCV7 period (P < .001). The rates of IPD among adults due to non-PCV7 serotypes increased from 8.4 to 9.7 episodes per 100,000 population between the pre-PCV7 period and the early PCV7 period (P = .15) and then to 15.3 episodes per 100,000 population in the late PCV7 period (P < .001); IPD due to PCV7 serotypes decreased from 5.6 to 4.9 episodes per 100,000 population between the pre-PCV7 period and the early PCV7 period (P = .3), then to 4.3 episodes per 100,000 population in the late PCV7 period (P = .056). Among people aged > or = 65 years, IPD due to PCV7 serotypes decreased from 19.5 to 14.6 episodes per 100,000 population between the pre-PCV7 period and the early PCV7 period (P = .13), then to 12.3 episodes per 100,000 population in the late PCV7 period (P = .02). A decrease in the prevalence of antibioticresistant pneumococci in the late PCV7 period was associated with a decrease in the prevalence of multidrugresistant PCV7 clones (Spain(23F)-ST81, Spain(6B)-ST90, and ST88(19F)) and an increase in the prevalence of non-PCV7 antibiotic-susceptible clones (ST306(1), ST191(7F), ST989(12F), and ST433(22F)).
CONCLUSIONS: Rates of IPD among adults increased in Barcelona in the late PCV7 period, coinciding with a clonal expansion of non-PCV7 serotypes. In contrast, rates of IPD caused by PCV7 serotypes decreased among people aged > or = 65 years, which suggests the development of a herd immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19035779     DOI: 10.1086/594125

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  58 in total

1.  Serotype distribution and antimicrobial resistance of invasive pneumococcal disease strains in the Comunidad Valenciana, Spain, during the winter of 2009-2010: low PCV7 coverage and high levofloxacin resistance.

Authors:  C M Gant; A W Rosingh; J L López-Hontangas; M van der Heijden; F González-Morán; J J E Bijlsma; E Canton
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

2.  Susceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccine.

Authors:  Asunción Fenoll; Lorenzo Aguilar; María-José Giménez; María-Dolores Vicioso; Olga Robledo; Juan-José Granizo; Pilar Coronel
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 3.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  Association Between Local Pediatric Vaccination Rates and Patterns of Pneumococcal Disease in Adults.

Authors:  Sundia Cassandra Pingali; Joshua L Warren; Aimee M Mead; Nancy Sharova; Susan Petit; Daniel M Weinberger
Journal:  J Infect Dis       Date:  2015-08-26       Impact factor: 5.226

Review 5.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

6.  Vaccination for the prevention of pneumococcal meningitis.

Authors:  Allan R Tunkel
Journal:  Curr Infect Dis Rep       Date:  2009-07       Impact factor: 3.725

7.  Serotype and genotype replacement among macrolide-resistant invasive Pneumococci in adults: mechanisms of resistance and association with different transposons.

Authors:  Laura Calatayud; Carmen Ardanuy; Fe Tubau; Dora Rolo; Immaculada Grau; Román Pallarés; Rogelio Martín; Josefina Liñares
Journal:  J Clin Microbiol       Date:  2010-02-10       Impact factor: 5.948

8.  The Alere BinaxNOW Pneumococcal Urinary Antigen Test: Diagnostic Sensitivity for Adult Pneumococcal Pneumonia and Relationship to Specific Serotypes.

Authors:  Hisashi Shoji; Arnau Domenech; Antonella Francesca Simonetti; Aida González; Dolores García-Somoza; Meritxell Cubero; Sara Martí; Masayuki Maeda; Fe Tubau; Josefina Liñares; Maria Angeles Domínguez; Jordi Carratalà; Carmen Ardanuy
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

9.  Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.

Authors:  Pawel Grzesiowski; Raquel Aguiar-Ibáñez; Aleksandra Kobryń; Laure Durand; Pierre-Emmanuel Puig
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 10.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.